- Home
- FMS vs ROIV Comparison
FMS vs ROIV Comparison
Compare FMS & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FMS | ROIV |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | Germany | United Kingdom |
| Employees | N/A | N/A |
| Industry | Misc Health and Biotechnology Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.5B | 14.1B |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | FMS | ROIV |
|---|---|---|
| Price | $23.60 | $22.92 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | ★ $30.00 | $24.31 |
| AVG Volume (30 Days) | 475.7K | ★ 7.4M |
| Earning Date | 11-04-2025 | 11-10-2025 |
| Dividend Yield | ★ 2.40% | N/A |
| EPS Growth | ★ 8.62 | N/A |
| EPS | ★ 2.86 | N/A |
| Revenue | ★ $23,046,819,198.00 | $20,329,000.00 |
| Revenue This Year | $2.12 | N/A |
| Revenue Next Year | $2.92 | $376.94 |
| P/E Ratio | $16.00 | ★ N/A |
| Revenue Growth | ★ 2.10 | N/A |
| 52 Week Low | $22.05 | $8.73 |
| 52 Week High | $30.46 | $23.23 |
Technical Indicators
Market Signals| Indicator | FMS | ROIV |
|---|---|---|
| Relative Strength Index (RSI) | 46.86 | 71.54 |
| Support Level | $22.63 | $20.14 |
| Resistance Level | $23.88 | $21.48 |
| Average True Range (ATR) | 0.29 | 0.79 |
| MACD | 0.14 | 0.14 |
| Stochastic Oscillator | 72.79 | 85.33 |
Price Performance
Historical ComparisonAbout FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.